Crisil assigns AA rating to NCD programmes of IPCA Laboratories

27 Sep 2011 Evaluate

Credit rating agency, Crisil has assigned ‘AA/Stable’ rating to one of the two Rs 50 crore non-convertible debenture (NCD) programmes of IPCA Laboratories, while reaffirming its ratings on the company’s other Rs 50 crore NCD programme and bank facilities at ‘AA/Stable/CRISIL A1+’.

The ratings continue to reflect the company’s well-diversified business profile across therapeutic segments and geographies, established market position in the domestic formulations segment and international market, and integrated operations, which are expected to help the company maintain its healthy financial risk profile, which is marked by robust capital structure and healthy debt protection metrics.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1585.60 1.35 (0.09%)
23-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1340.80
Cipla 1476.45
Lupin 2160.20
Zydus Lifesciences 972.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.